KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Assets (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Assets for 15 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 6.18% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 6.18% increase, with the full-year FY2025 number at $1.5 billion, up 6.18% from a year prior.
  • Assets was $1.5 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.8 billion in Q1 2023 to a low of $1.3 billion in Q4 2023.
  • A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 define the central range for Assets.
  • Peak YoY movement for Assets: grew 26.69% in 2021, then fell 27.22% in 2024.
  • Supernus Pharmaceuticals' Assets stood at $1.7 billion in 2021, then rose by 0.79% to $1.7 billion in 2022, then dropped by 24.95% to $1.3 billion in 2023, then rose by 7.08% to $1.4 billion in 2024, then grew by 6.18% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Assets are $1.5 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).